-
Mashup Score: 0Investigators Look to Add Duvelisib to Treatment Arsenal of Rare T-Cell Lymphoma Subtype - 4 day(s) ago
Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
E. Gabriela Chiorean, MD, FASCO, highlights the significance of encorafenib plus cetuximab and mFOLFOX6’s FDA approval in BRAF V600E-mutated metastatic CRC.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
“Nevertheless, BRAF V600E-mutated CRC tends to be quite aggressive, and overall survival [OS] with first-line chemotherapy, even with FOLFIRINOX plus bevacizumab, is less than 18 months,” said E. Gabriela Chiorean, MD, FASCO, of @fredhutch. #crcsm https://t.co/AtycERbQbU
-
-
Mashup Score: 0Revisit the Top Presentations and Biggest Data From the 2025 Gastrointestinal Cancers Symposium - 4 day(s) ago
A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
.@ASCO #GI25 wrapped up after 3 days of impactful presentations highlighting emerging data from across the field. In case you missed them in San Francisco, here are some of the top abstracts presented at this year’s meeting. #crcsm #pancsm #hpbcsm #stcsm https://t.co/qsZZK9JRv2 https://t.co/aB2X9WNia5
-
-
Mashup Score: 0Signatera ctDNA Assay Found to Influence Adjuvant Chemo Decision-Making in Stage II/III CRC - 4 day(s) ago
Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Although 83.7% of treatment decisions remained unchanged, findings from Signatera influenced adjuvant chemotherapy usage in 16.3% of cases for stage II/III CRC. @ASCO #GI25 #crcsm #oncology #MedTwitter https://t.co/WRKwTC6xMy
-
-
Mashup Score: 0
Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Encorafenib/cetuximab and chemotherapy achieved an ORR of 60.9% vs 40.0% with chemotherapy alone for patients with mCRC harboring BRAF V600E mutations. @ASCO @skopetz @MDAndersonNews #GI25 #crcsm https://t.co/DVPKGIcKUC https://t.co/1ww0UFxYQt
-
-
Mashup Score: 0Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets - 4 day(s) ago
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The contribution of balstilimab to botensilimab in patients with MSS mCRC without liver metastases has been confirmed in a phase 2 study. @ASCO @mgfakih @cityofhope #GI25 #crcsm #oncology https://t.co/0Az0mWHtWK
-
-
Mashup Score: 0Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer - 4 day(s) ago
Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
ICYMI: @WainbergZev of @UCLAHealth discusses findings from the phase 2/3 ASPEN-06 trial of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer. WATCH: https://t.co/Rb9jVNVIzN #gastric #oncology #MedEd
-
-
Mashup Score: 0Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP - 4 day(s) ago
Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
In today’s episode of #OncLiveOnAir, @jhaveri_komal of @MSKCancerCenter discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer. LISTEN NOW: https://t.co/bll1MDgyOs #bcsm #oncology https://t.co/XAyotMtJdO
-
-
Mashup Score: 0
Treatment with a single cycle of neoadjuvant pembrolizumab demonstrated a pCR rate of 44% in patients with dMMR colon cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Grade 3 AEs were observed in 8% of patients, with 4% experiencing immune-related grade 3 AEs, among patients with dMMR colon cancer treated with neoadjuvant pembrolizumab administered in a single cycle. @ASCO #GI25 #crcsm #oncology https://t.co/KOvF8nP9WN https://t.co/WCWJ2ZiKyY
-
-
Mashup Score: 0
Aspirin reduced the risk of disease recurrence in colorectal cancer harboring PI3K pathway alterations.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The phase 3 ALASCCA trial met its primary end point of reducing the risk for disease recurrence by 51% in patients with colorectal cancer with PIK3CA exon 9/20 mutations. @ASCO #GI25 #crcsm #oncology https://t.co/KerSRyMwoA
-
Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype. Read more here: https://t.co/XGohTRzo4F https://t.co/diN51TftSm